Skip to main content
Maja Krajinovic on Muck Rack

Maja Krajinovic

As seen in: Nature, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maja

Contact Maja, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

HLA-B*15:01 and HLA-DRB1* 07:01 as novel markers of acute GVHD in pediatric HSCT

|
By Covida Mootoosamy, Marc Ansari, Vincent Gagné, Pascal St-Onge, Patrick Beaulieu, Yves Théorêt, Tiago Nava, Vid Mlakar, Yvonne Gloor, Jean Villard, Jean-Hugues Dalle, Victor A Lewis, Krzysztof Kałwak, Daniel Sinnett, Henrique Bittencourt, Maja Krajinovic, Pascal Tremblay-Dauphinais, Jaap-Jan Boelens, Robbert G. M. Bredius
| Nature Verified
Access to this article via EBSCO Subscription Services PO Box 1943 is not available. To The Editor Acute graft-versus-host disease (aGVHD) is a common and potentially severe complication occurring in up to 60% of patients following allogeneic hematopoietic stem cell transplantation (HSCT) [1]. In pediatric recipients, grade II–IV aGVHD occurs in roughly half of patients within 100 days post-transplant and contributes to significant mortality (up to ~56% in steroid-refractory cases) [1].
Open in Who Shared Issue with article?

DNA Hybridization Specificity: A Review and Proposed Framework Based on Stack-Supported Complementary Islands

|
By Ivan Brukner, Maja Krajinovic
| preprints.org
This open access article is published under a , which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Open in Who Shared View Duplicates (622) Issue with article?

Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy

|
By Siyu Liu, Maja Krajinovic, Marc Ansari, Kathryn L. Bradford
| tctjournal.org
Highlights • Low-dose busulfan can open the bone marrow niche in the setting of gene therapy. • Body surface area- and weight-based dosing resulted in variable busulfan plasma exposure. • Therapeutic drug monitoring-based dosing resulted in consistent plasma exposure. • Busulfan clearance increased as subject age increased from birth to 18 months.
Open in Who Shared Issue with article?
See all 6 articles